Full Fed. Circ. Won't Review Becton's Wins On Drug Dosing IP

Law360 (May 10, 2021, 2:06 PM EDT) -- The full Federal Circuit on Monday denied a petition from Baxter Corp. Englewood for review of a panel decision affirming Patent Trial and Appeal Board rulings that invalidated two of the company's medication dosing patents in challenges brought by Becton Dickinson & Co.

The full court denied the bid for rehearing in a two-page order, thereby rejecting Baxter's argument that the PTAB had violated the Administrative Procedure Act because it impermissibly relied on invalidity arguments that Becton had not made in its inter partes review petitions. The decision further bolsters Becton's effort to beat back a 2017 infringement suit from Baxter...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!